Cargando…

Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

BACKGROUND: Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results in fluctuating CSF Aβ levels that have a tendency to increase compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Broeck, Bianca, Timmers, Maarten, Ramael, Steven, Bogert, Jennifer, Shaw, Leslie M., Mercken, Marc, Slemmon, John, Van Nueten, Luc, Engelborghs, Sebastiaan, Streffer, Johannes Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875639/ https://www.ncbi.nlm.nih.gov/pubmed/27206648 http://dx.doi.org/10.1186/s13195-016-0184-z

Ejemplares similares

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016)

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
por: Timmers, Maarten, et al.
Publicado: (2017)

Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus
por: Lukkarinen, Heikki, et al.
Publicado: (2021)

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
por: Novak, Gerald, et al.
Publicado: (2020)

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time
por: Triana-Baltzer, Gallen, et al.
Publicado: (2022)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
por: Timmers, Maarten, et al.
Publicado: (2018)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
por: Temmerman, Joke, et al.
Publicado: (2023)

Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson’s Disease
por: Tkaczynska, Zuzanna, et al.
Publicado: (2020)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease
por: Niemantsverdriet, Ellis, et al.
Publicado: (2016)

Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer’s Disease but Are Not Correlated with Cognitive Decline
por: Nous, Amber, et al.
Publicado: (2021)

Normative data from linear and nonlinear quantile regression in CANTAB: Cognition in mid-to-late life in an epidemiological sample
por: Abbott, Rosemary A., et al.
Publicado: (2018)

Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration
por: Goossens, Joery, et al.
Publicado: (2018)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort
por: Niemantsverdriet, Ellis, et al.
Publicado: (2018)

Viral Metagenomics on Cerebrospinal Fluid
por: Edridge, Arthur W. D., et al.
Publicado: (2019)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

Multi-Omics Approach to Elucidate Cerebrospinal Fluid Changes in Dogs with Intervertebral Disc Herniation
por: Horvatić, Anita, et al.
Publicado: (2021)

Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests
por: Borghys, Herman, et al.
Publicado: (2017)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
por: Arnerić, Stephen P., et al.
Publicado: (2016)

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

Cerebrospinal Fluid
por: Bailey, Cleta Sue, et al.
Publicado: (1997)

Cerebrospinal Fluid
por: Vernau, William, et al.
Publicado: (2008)

The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease
por: Trombetta, Bianca A., et al.
Publicado: (2018)

Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort
por: Gijselinck, Ilse, et al.
Publicado: (2015)

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
por: Westwood, Sarah, et al.
Publicado: (2017)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

Will clinical parameters reliably predict external ventricular drain-associated ventriculitis: Is frequent routine cerebrospinal fluid surveillance necessary?
por: Hariri, Omid, et al.
Publicado: (2017)

The cerebrospinal fluid in retinoblastoma.
por: Ifekwunigwe, A. E., et al.
Publicado: (1966)

Cannot write session to /tmp/vufind_sessions/sess_v7bg9i63laffptoa5nm91nhk51